WallStSmart

Ironwood Pharmaceuticals Inc (IRWD)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 5727% more annual revenue ($17.26B vs $296.15M). TEVA leads profitability with a 8.2% profit margin vs 8.1%. IRWD trades at a lower P/E of 20.3x. TEVA earns a higher WallStSmart Score of 73/100 (B).

IRWD

Hold

47

out of 100

Grade: D+

Growth: 3.3Profit: 6.0Value: 8.3Quality: 5.0

TEVA

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 7.5Value: 10.0Quality: 4.8
Piotroski: 6/9Altman Z: 0.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IRWDUndervalued (+36.8%)

Margin of Safety

+36.8%

Fair Value

$7.02

Current Price

$3.04

$3.98 discount

UndervaluedFair: $7.02Overvalued
TEVAUndervalued (+39.4%)

Margin of Safety

+39.4%

Fair Value

$56.63

Current Price

$29.46

$27.17 discount

UndervaluedFair: $56.63Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IRWD0 strengths · Avg: 0/10

No standout strengths identified

TEVA4 strengths · Avg: 8.3/10
Return on EquityProfitability
20.8%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
27.3%8/10

Strong operational efficiency at 27.3%

EPS GrowthGrowth
40.0%8/10

Earnings expanding 40.0% YoY

Free Cash FlowQuality
$1.02B8/10

Generating 1.0B in free cash flow

Areas to Watch

IRWD3 concerns · Avg: 2.3/10
Market CapQuality
$495.70M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-5.8%2/10

ROE of -5.8% — below average capital efficiency

Revenue GrowthGrowth
-47.3%2/10

Revenue declined 47.3%

TEVA1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
0.282/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : IRWD

IRWD has a balanced fundamental profile.

Bull Case : TEVA

The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bear Case : IRWD

The primary concerns for IRWD are Market Cap, Return on Equity, Revenue Growth.

Bear Case : TEVA

The primary concerns for TEVA are Altman Z-Score.

Key Dynamics to Monitor

TEVA carries more volatility with a beta of 0.72 — expect wider price swings.

TEVA is growing revenue faster at 11.4% — sustainability is the question.

TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TEVA scores higher overall (73/100 vs 47/100) and 11.4% revenue growth. IRWD offers better value entry with a 36.8% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ironwood Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?